Trending...
- Massachusetts: Governor Maura Healey Lifts States of Emergency
- Boston: Mayor Wu Announces New Roxbury Neighborhood Liaison, Asha Janay
- Boston: Councilor Sharon Durkan Delivers Her Maiden Speech
CAMBRIDGE, Mass. ~ Seres Therapeutics, Inc. (Nasdaq: MCRB) announced on April 5, 2023 that the Compensation and Talent Committee of its board of directors granted inducement equity grants to three new employees. The grants consist of stock options to purchase 11,000 shares of common stock and restricted stock units (RSUs) covering an aggregate of 11,000 shares of its common stock.
The grants are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the "Inducement Plan"). The Inducement Plan was adopted by Seres' board of directors in December 2022 and is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4).
More on Boston Chron
The stock options have an exercise price of $5.61 per share and will vest as to 25% of the total number of shares subject to the option on the first anniversary of the applicable individual's date of hire and as to 6.25% of the total number of shares subject to the option upon a completion of each three full months of service to the Company thereafter. The RSUs vest as to 25% on the first 15th day after a calendar month that immediately follows the first anniversary date and as to an additional 6.25% upon completion each three full months thereafter.
Seres Therapeutics is a leading microbiome therapeutics company that is committed to providing innovative treatments for patients with serious diseases.
The grants are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the "Inducement Plan"). The Inducement Plan was adopted by Seres' board of directors in December 2022 and is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4).
More on Boston Chron
- Sidow Sobrino Announces 12th Album, "Seminal"
- Boston Public Health Commission Encourages People to Get the Flu Shot Ahead of Flu Season
- Asha Therapeutics Selected as a BLUE KNIGHT™ Company by Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA)
- Heartland Soccer Association and VidSport Launch Groundbreaking Live Streaming Service at Garmin Olathe Soccer Complex
- Massachusetts Wins Proposal to Host Northeast Microelectronics Hub through Federal CHIPS and Science Act
The stock options have an exercise price of $5.61 per share and will vest as to 25% of the total number of shares subject to the option on the first anniversary of the applicable individual's date of hire and as to 6.25% of the total number of shares subject to the option upon a completion of each three full months of service to the Company thereafter. The RSUs vest as to 25% on the first 15th day after a calendar month that immediately follows the first anniversary date and as to an additional 6.25% upon completion each three full months thereafter.
Seres Therapeutics is a leading microbiome therapeutics company that is committed to providing innovative treatments for patients with serious diseases.
Filed Under: Business
0 Comments
Latest on Boston Chron
- HERITAGE FINANCIAL A BARRON'S TOP 100 INDEPENDENT ADVISOR
- Trinity Prairie Real Estate Lists Mesmerizing 16.78-Acre Estate in Colleyville, Texas
- Boston: THE MARY ELIZA PROJECT: WARD 16 VOTER RECORDS NOW AVAILABLE
- Mayor Wu announces a new pilot program to decarbonize Boston's housing stock
- Boston: SCHOOLS URGED TO REGISTER FOR THE BCYF SPELLING BEE
- ACEC/MA Announces Gold Engineering Excellence Award Winners for 2023
- Rhody Rug Revolutionizes Online Shopping Experience with the Launch of their New Direct-to-Consumer Website
- Keches Law Group Attorneys Recognized by Best Lawyers® in 2024 in America
- Long Island businessman turned recording artist, John Beyer, to release his first love song aptly titled, …"Love You More"
- The 2023 CGI Integrated Care Conference Explores Opportunities in Healthcare Improvement Discovered as a Result of the COVID-19 Pandemic
- CVS Health appoints Michael F. Mahoney to its Board of Directors
- Exploring the World of Web3? Lympid Puts Users Front and Center
- JetBlue Adds Amsterdam Service from Boston Starting Today
- Boston: Mayor Wu, Secretary Ed Augustus, and MassHousing Celebrate the Grand Opening of B'Nai B'rith Housing's Parkway 1208 in West Roxbury
- "Regenerating Life": documentary film challenges current assumptions about climate change
- Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Massachusetts Receives More than $22 Million from USDA to Expand Access to Trees and Green Space
- Flint's Got Talent Returns To Showcase Creativity In Community
- Boston: Chemist Applications Available On Fire Prevention Portal Starting October 1, 2023
- Autonomous eVTOLs $25 Billion Market by 2030